Literature DB >> 32399419

Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies.

Chao-Ran Li1, Lang Chen2, Long-Fei Wang3, Bin Yan1, You-Ling Liang1, Jing Luo1.   

Abstract

AIM: To conduct a systematic review and Meta-analysis to examine the association between uveitis and psoriatic disease, and to evaluate whether one condition predisposes individuals to the other.
METHODS: We performed a comprehensive search of PubMed and EMBASE to identify cohort studies examining the association between uveitis and psoriatic disease [psoriasis and/or psoriatic arthritis (PsA)]. We used a random-effects model to calculate the pooled relative risks (RRs) adjusted for confounders, along with the 95% confidence intervals (CIs).
RESULTS: This Meta-analysis included a total of 6 studies and a maximum of 80 178 648 participants. Compared with non-psoriatic controls, uveitis risk was significantly elevated in patients with psoriasis (RR=1.49; 95%CI: 1.08-2.07), and PsA (RR=3.16; 95%CI: 2.16-4.63). Furthermore, pre-existing uveitis was associated with a significantly increased risk of psoriasis (RR=1.62; 95%CI: 1.44-1.83), and PsA (RR=4.44; 95%CI: 3.52-5.60).
CONCLUSION: The results of this systematic review and Meta-analysis suggest an overall positive bidirectional association between uveitis and psoriatic disease (psoriasis and PsA), warranting increased awareness among clinicians involved in the management of these two conditions. Therefore, there remains a need for more detailed studies of the possible common pathogenesis of psoriatic disease and uveitis. International Journal of Ophthalmology Press.

Entities:  

Keywords:  Meta-analysis; psoriasis; psoriatic arthritis; risk; uveitis

Year:  2020        PMID: 32399419      PMCID: PMC7137715          DOI: 10.18240/ijo.2020.04.19

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  67 in total

1.  Elevated serum levels of interleukin-17A in uveitis patients.

Authors:  Shayma Jawad; Baoying Liu; Elvira Agron; Robert B Nussenblatt; H Nida Sen
Journal:  Ocul Immunol Inflamm       Date:  2013-08-19       Impact factor: 3.070

2.  Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.

Authors:  Andrew D Dick; Ilknur Tugal-Tutkun; Stephen Foster; Manfred Zierhut; S H Melissa Liew; Vladimir Bezlyak; Sofia Androudi
Journal:  Ophthalmology       Date:  2013-01-03       Impact factor: 12.079

Review 3.  Targeting IL-17 and TH17 cells in chronic inflammation.

Authors:  Pierre Miossec; Jay K Kolls
Journal:  Nat Rev Drug Discov       Date:  2012-10       Impact factor: 84.694

Review 4.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

5.  Risk of Uveitis Among People With Psoriasis: A Nationwide Cohort Study.

Authors:  Ching-Chi Chi; Tao-Hsin Tung; Jui Wang; Yu-Sheng Lin; Yu-Fen Chen; Tsui-Kan Hsu; Shu-Hui Wang
Journal:  JAMA Ophthalmol       Date:  2017-05-01       Impact factor: 7.389

6.  Association of Psoriatic Disease With Uveitis: A Danish Nationwide Cohort Study.

Authors:  Alexander Egeberg; Usman Khalid; Gunnar Hilmar Gislason; Lotus Mallbris; Lone Skov; Peter Riis Hansen
Journal:  JAMA Dermatol       Date:  2015-11       Impact factor: 10.282

7.  Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.

Authors:  Quan Dong Nguyen; Pauline T Merrill; Glenn J Jaffe; Andrew D Dick; Shree Kumar Kurup; John Sheppard; Ariel Schlaen; Carlos Pavesio; Luca Cimino; Joachim Van Calster; Anne A Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Antoine P Brézin
Journal:  Lancet       Date:  2016-08-16       Impact factor: 79.321

Review 8.  Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.

Authors:  James T Rosenbaum
Journal:  Clin Rheumatol       Date:  2015-05-08       Impact factor: 2.980

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

10.  The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques.

Authors:  B Trusko; J Thorne; D Jabs; R Belfort; A Dick; S Gangaputra; R Nussenblatt; A Okada; J Rosenbaum
Journal:  Methods Inf Med       Date:  2013-02-08       Impact factor: 2.176

View more
  3 in total

1.  Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.

Authors:  Philip J Mease; Atul A Deodhar; Désirée van der Heijde; Frank Behrens; Alan J Kivitz; Jeffrey Neal; Jonghyeon Kim; Shalabh Singhal; Miroslawa Nowak; Subhashis Banerjee
Journal:  Ann Rheum Dis       Date:  2022-03-03       Impact factor: 27.973

2.  Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses.

Authors:  Yun Zhou; Lixian Zhong; Lianli Shen; Sisi Chen; Qiuting Zeng; Leizhen Lai; Shaohui Tang
Journal:  Front Med (Lausanne)       Date:  2022-08-29

3.  Uveitis and nail psoriasis in a patient without articular involvement: a case report.

Authors:  Juan Sebastián Pineda-Sierra; Luisa Fernanda Peña-Pulgar; Carlos Cifuentes-González; William Rojas-Carabali; Alejandra de-la-Torre
Journal:  BMC Ophthalmol       Date:  2022-09-24       Impact factor: 2.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.